Increasing GLP-1–Induced β-Cell Proliferation by Silencing the Negative Regulators of Signaling cAMP Response Element Modulator-α and DUSP14
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
OBJECTIVE—Glucagon-like peptide-1 (GLP-1) is a growth and differentiation factor for mature β-cells and their precursors. However, the overall effect of GLP-1 on increasing β-cell mass in both in vivo and in vitro conditions is relatively small, and augmenting this effect would be beneficial for the treatment or prevention of type 1 and type 2 diabetes. Here, we searched for cellular mechanisms that may limit the proliferative effect of GLP-1 and tested whether blocking them could increase β-cell proliferation. RESEARCH DESIGN AND METHODS—We examined GLP-1–regulated genes in βTC-Tet cells by cDNA microarrays. To assess the effect of some of these gene on cell proliferation, we reduced their expression using small heterogenous RNA in β-cell lines and primary mouse islets and measured [3H]thymidine or 5′-bromo-2′-deoxyuridine incorporation. RESULTS—We identified four negative regulators of intracellular signaling that were rapidly and strongly activated by GLP-1: the regulator of G-protein–signaling RGS2; the cAMP response element-binding protein (CREB) antagonists cAMP response element modulator (CREM)-α and ICERI; and the dual specificity phosphatase DUSP14, a negative regulator of the mitogen-activated protein kinase (MAPK)/extracellular signal–regulated kinase 1/2 (ERK1/2) pathway. We show that knockdown of CREMα or DUSP14 or expression of a dominant-negative form of DUSP14 increased β-cell line proliferation and enhanced the GLP-1–induced proliferation of primary β-cells. CONCLUSIONS—Together, our data show that 1) the cAMP/protein kinase A/CREB and MAPK/ERK1/2 pathways can additively control β-cell proliferation, 2) β-cells have evolved several mechanisms limiting GLP-1–induced cellular proliferation, and 3) blocking these mechanisms increases the positive effect of GLP-1 on β-cell mass.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“An analogous strategy, i.e. the inhibition of an inhibitor, has been used recently as a solution to enhance β-cell proliferation by attenuating signals that restrain GLP-1 action [72].”
From Expansion of β-cell mass in response to pregnancy (2010) · cites this paper as [72]
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482 · cited 4×
“P values were adjusted for multiple testing using the false discovery rate method proposed by Benjamini and Hochberg (24).”
MethodInfluentialA System for Stable Expression of Short Interfering RNAs in Mammalian Cells
Brummelkamp, T. R., Bernards, R., & Agami, R. (2002) · Science · doi:10.1126/science.1068999 · Cited by 4,291 · cited 4×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluentialβ-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
Adult pancreatic β-cells are formed by self-duplication rather than stem-cell differentiation
Dor, Y., Brown, J., Martinez, O. I., & Melton, D. A. (2004) · Nature · doi:10.1038/nature02520 · Cited by 2,219
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559 · cited 1×
“Increasing the mass of existing -cells by interfering with the mechanisms we have described here could be used to improve GLP-1–based therapy of type 2 diabetes (47,48) so long as reducing the expression of these negative regulators could be finely tuned so as not to overcome the natural feedback loops that normally p…”
BackgroundBuse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346
Xu, G., Stoffers, D. A., Habener, J. F., & Bonner-Weir, S. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2270 · Cited by 1,209
Kendall, D. M., Riddle, M. C., Rosenstock, J., Zhuang, D., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1083 · Cited by 1,177 · cited 1×
“Increasing the mass of existing -cells by interfering with the mechanisms we have described here could be used to improve GLP-1–based therapy of type 2 diabetes (47,48) so long as reducing the expression of these negative regulators could be finely tuned so as not to overcome the natural feedback loops that normally p…”
BackgroundThorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906 · cited 4×
“The -cell GLP-1 receptor is a Gs-protein–coupled receptor (16) that activates the cAMP/protein kinase A (PKA)/cAMP response element-binding protein (CREB) pathway (17) but also the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (18,19) by a mechanism that involves ac…”
BackgroundMethodSelf-citationWiznerowicz, M., & Trono, D. (2003) · Journal of Virology · doi:10.1128/jvi.77.16.8957-8951.2003 · Cited by 701 · cited 4×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluentialMechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680 · cited 3×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
MethodHolz IV, G. G., Kiihtreiber, W. M., & Habener, J. F. (1993) · Nature · doi:10.1038/361362a0 · Cited by 594 · cited 1×
“These genes are induced by the cAMP pathway and potentiated by influx of Ca(2) , suggesting that their induction is more potent in mature -cells than in their precursors because Ca(2) influx after GLP-1 treatment is a characteristic of well-differentiated -cells (43).”
BackgroundStoffers, D. A., Kieffer, T. J., Hussain, M. A., Drucker, D. J., Bonner-Weir, S., Habener, J. F., & Egan, J. M. (2000) · Diabetes · doi:10.2337/diabetes.49.5.741 · Cited by 576
Growth and Regeneration of Adult β Cells Does Not Involve Specialized Progenitors
Teta, M., Rankin, M. M., Long, S. Y., Stein, G. M., & Kushner, J. A. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.04.011 · Cited by 551
The role of interleukin-1 in the pathogenesis of IDDM
Mandrup-Poulsen, T. (1996) · Diabetologia · doi:10.1007/bf00400649 · Cited by 543 · cited 1×
“Diabetes 57:584–593, 2008 A reduction in pancreatic -cell mass and function triggers the overt phase of type 2 diabetes (1,2), whereas the destruction of -cells by autoimmune attack causes type 1 diabetes (3).”
BackgroundcAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2
Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed, J., Walker, J., Lin, X., White, M., & Montminy, M. (2003) · Genes & Development · doi:10.1101/gad.1097103 · Cited by 543
Buteau, J., Roduit, R., Susini, S., & Prentki, M. (1999) · Diabetologia · doi:10.1007/s001250051238 · Cited by 413 · cited 5×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
MethodResultInfluentialButeau, J., Foisy, S., Joly, E., & Prentki, M. (2003) · Diabetes · doi:10.2337/diabetes.52.1.124 · Cited by 411 · cited 4×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluentialTranscription Factors Responsive to cAMP
Sassone-Corsi, P. (1995) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cb.11.110195.002035 · Cited by 381 · cited 2×
“CREM and ICERI are repressors of cAMP-induced, CREB-dependent transcription (37).”
BackgroundTourrel, C., Bailbé, D., Meile, M.-J., Kergoat, M., & Portha, B. (2001) · Diabetes · doi:10.2337/diabetes.50.7.1562 · Cited by 362
Pospisilik, J. A., Martin, J., Doty, T., Ehses, J. A., Pamir, N., Lynn, F. C., Piteau, S., Demuth, H.-U., McIntosh, C. H. S., & Pederson, R. A. (2003) · Diabetes · doi:10.2337/diabetes.52.3.741 · Cited by 332
Zhou, J., Wang, X., Pineyro, M. A., & Egan, J. M. (1999) · Diabetes · doi:10.2337/diabetes.48.12.2358 · Cited by 319
Abraham, E. J. (2002) · Endocrinology · doi:10.1210/en.143.8.3152 · Cited by 310 · cited 3×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
MethodTourrel, C., Bailbe, D., Lacorne, M., Meile, M.-J., Kergoat, M., & Portha, B. (2002) · Diabetes · doi:10.2337/diabetes.51.5.1443 · Cited by 285 · cited 3×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
MethodSinnarajah, S., Dessauer, C. W., Srikumar, D., Chen, J., Yuen, J., Yilma, S., Dennis, J. C., Morrison, E. E., Vodyanoy, V., & Kehrl, J. H. (2001) · Nature · doi:10.1038/35059104 · Cited by 259 · cited 1×
“RGS2 is a GTPaseactivating protein that inactivates G (39) and also directly inhibits the activity of some adenylyl cyclases (40).”
BackgroundEfrat, S., Fusco-DeMane, D., Lemberg, H., al Emran, O., & Wang, X. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3576 · Cited by 257 · cited 6×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluentialButeau, J., Foisy, S., Rhodes, C. J., Carpenter, L., Biden, T. J., & Prentki, M. (2001) · Diabetes · doi:10.2337/diabetes.50.10.2237 · Cited by 252 · cited 3×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
MethodBosco, D., Meda, P., Halban, P. A., & Rouiller, D. G. (2000) · Diabetes · doi:10.2337/diabetes.49.2.233 · Cited by 229
Self-citationHui, H., Wright, C., & Perfetti, R. (2001) · Diabetes · doi:10.2337/diabetes.50.4.785 · Cited by 223
GOTOH, M., MAKI, T., SATOMI, S., PORTER, J., BONNER-WEIR, S., OʼHARA, C. J., & MONACO, A. P. (1987) · Transplantation · doi:10.1097/00007890-198705000-00024 · Cited by 218 · cited 4×
“Islets from male C57BL/6 mice were isolated by collagenase digestion (32) and Histopaque density gradient purification.”
MethodInfluentialAll β Cells Contribute Equally to Islet Growth and Maintenance
Brennand, K., Huangfu, D., & Melton, D. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050163 · Cited by 210
Kang, G., Chepurny, O. G., & Holz, G. G. (2001) · The Journal of Physiology · doi:10.1111/j.1469-7793.2001.0375c.xd · Cited by 204
RGS proteins: more than just GAPs for heterotrimeric G proteins
De Vries, L. (1999) · Trends in Cell Biology · doi:10.1016/s0962-8924(99)01515-9 · Cited by 202 · cited 1×
“RGS2 is a GTPaseactivating protein that inactivates G (39) and also directly inhibits the activity of some adenylyl cyclases (40).”
Thorens, B., Guillam, M.-T., Beermann, F., Burcelin, R., & Jaquet, M. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002908200 · Cited by 185 · cited 4×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodSelf-citationGomez, E., Pritchard, C., & Herbert, T. P. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m209165200 · Cited by 162
Dickson, L. M., & Rhodes, C. J. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00031.2004 · Cited by 159
Regulation of ERK1 and ERK2 by Glucose and Peptide Hormones in Pancreatic β Cells
Arnette, D., Gibson, T. B., Lawrence, M. C., January, B., Khoo, S., McGlynn, K., Vanderbilt, C. A., & Cobb, M. H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m301174200 · Cited by 126 · cited 4×
“The -cell GLP-1 receptor is a Gs-protein–coupled receptor (16) that activates the cAMP/protein kinase A (PKA)/cAMP response element-binding protein (CREB) pathway (17) but also the mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase 1/2 (ERK1/2) pathway (18,19) by a mechanism that involves ac…”
BackgroundMethodInfluentialSerre, V., Dolci, W., Schaerer, E., Scrocchi, L., Drucker, D., Efrat, S., & Thorens, B. (1998) · Endocrinology · doi:10.1210/endo.139.11.6295 · Cited by 110 · cited 13×
“Different shRNAs were subcloned in the pSUPER vector and tested for their capacity to reduce the expression of CREM and DUSP14 in transiently transfected HEK-293T cells, as assessed by quantitative RT-PCR (data not shown) and Western blot analysis.”
BackgroundSelf-citationMarti, F., Krause, A., Post, N. H., Lyddane, C., Dupont, B., Sadelain, M., & King, P. D. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.197 · Cited by 108 · cited 7×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluentialFunctional analysis of a conditionally transformed pancreatic beta-cell line.
Fleischer, N., Chen, C., Surana, M., Leiser, M., Rossetti, L., Pralong, W., & Efrat, S. (1998) · Diabetes · doi:10.2337/diabetes.47.9.1419 · Cited by 93 · cited 5×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
BackgroundMethodInfluentialRouiller, D. G., Cirulli, V., & Halban, P. A. (1990) · Experimental Cell Research · doi:10.1016/0014-4827(90)90019-7 · Cited by 89 · cited 5×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
MethodSelf-citationde Fourmestraux, V., Neubauer, H., Poussin, C., Farmer, P., Falquet, L., Burcelin, R., Delorenzi, M., & Thorens, B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m408014200 · Cited by 83 · cited 5×
“For microarray experiments, cDNAs were synthesized by reverse transcription of 5 g amplified RNA and labeled by an indirect procedure with Cy5 (GLP-1–treated samples) or Cy3 (control samples) as described previously (23).”
MethodSelf-citationTseng, C.-C., & Zhang, X.-Y. (1998) · Endocrinology · doi:10.1210/endo.139.11.6282 · Cited by 82
Inada, A., Hamamoto, Y., Tsuura, Y., Miyazaki, J.-I., Toyokuni, S., Ihara, Y., Nagai, K., Yamada, Y., Bonner-Weir, S., & Seino, Y. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.7.2831-2841.2004 · Cited by 75 · cited 1×
“It has been reported that expression of ICERI and ICERI is markedly increased in diabetes (41) and that transgenic overexpression of ICERI in pancreatic -cells causes early diabetes and reduced -cell proliferation (42), suggesting a role of the cAMP/PKA/CREB pathway in -cell proliferation.”
BackgroundCottet, S., Dupraz, P., Hamburger, F., Dolci, W., Jaquet, M., & Thorens, B. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m103235200 · Cited by 58 · cited 6×
“For analysis of signaling pathways, growth-arrested TC-Tet cells were incubated for 2 h in medium containing 1% FBS, medium was then changed and the incubations continued with combinations of 100 nmol/l GLP-1 (7-36)-amide, 10 mol/l H89, 50 mol/l PD98059, 50 nmol/l wortmannin, 10 mol/l forskolin, 50 mol/l Epac activato…”
MethodSelf-citationDifferential Sensitivity of Phosphatidylinositol 3-Kinase p110γ to Isoforms of G Protein βγ Dimers
Kerchner, K. R., Clay, R. L., McCleery, G., Watson, N., McIntire, W. E., Myung, C., & Garrison, J. C. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m406071200 · Cited by 56
Kaiser, Ν., CORCOS, A. P., Tur-Sinai, A., Ariav, Y., & Cerasi, E. (1988) · Endocrinology · doi:10.1210/endo-123-2-834 · Cited by 49 · cited 4×
“corneal endothelial cells (Novamed, Jerusalem, Israel) (33) or kept in suspen-”
BackgroundMethodInfluentialTranscriptional Repressors Are Increased in Pancreatic Islets of Type 2 Diabetic Rats
Inada, A., Yamada, Y., Someya, Y., Kubota, A., Yasuda, K., Ihara, Y., Kagimoto, S., Kuroe, A., Tsuda, K., & Seino, Y. (1998) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1998.9833 · Cited by 38 · cited 1×
“It has been reported that expression of ICERI and ICERI is markedly increased in diabetes (41) and that transgenic overexpression of ICERI in pancreatic -cells causes early diabetes and reduced -cell proliferation (42), suggesting a role of the cAMP/PKA/CREB pathway in -cell proliferation.”
Background
Cited by
The role of incretins in glucose homeostasis and diabetes treatment
Kim, W., & Egan, J. M. (2008) · Pharmacological Reviews · doi:10.1124/pr.108.000604 · Cited by 824
Dual-specificity phosphatases: critical regulators with diverse cellular targets
Patterson, K. I., Brummer, T., O'brien, P. M., & Daly, R. J. (2009) · Biochemical Journal · doi:10.1042/bj20082234 · Cited by 744
Expansion of β-cell mass in response to pregnancy
Rieck, S., & Kaestner, K. H. (2010) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2009.11.001 · Cited by 358
Agrawal, N., Delanoue, R., Mauri, A., Basco, D., Pasco, M., Thorens, B., & Léopold, P. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.03.003 · Cited by 206
“Real-time quantitative PCR was performed in a 20 ml reaction mixture including 13QuantiTectTM SYBRGreen PCR Master Mix (QIAGEN) and 10 pmol of each primer, as described (Klinger et al., 2008).”
MethodSelf-citationQuoyer, J., Longuet, C., Broca, C., Linck, N., Costes, S., Varin, E., Bockaert, J., Bertrand, G., & Dalle, S. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.067207 · Cited by 187
Metadata
- Authors
- Klinger, S., Poussin, C., Debril, M.-B., Dolci, W., Halban, P. A., & Thorens, B.
- Affiliations
- University of Lausanne (CH)
- University Hospital of Geneva (CH)
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2008-03-01
- Volume
- 57
- Issue
- 3
- Pages
- 584-593
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2140883834
- Cited by
- 86
- References
- 48
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 2 · 2023: 1 · 2022: 1 · 2021: 2 · 2020: 5 · 2019: 1 · 2018: 2 · 2017: 3 · 2016: 7 · 2015: 6 · 2014: 10 · 2013: 6 · 2012: 6
- FWCI
- 8.22
- Type
- journal article
- Language
- en
- Open access
- Licence
- cc-by
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- glucagon-like peptide-1, beta-cell proliferation, beta-cell mass, DUSP14, RGS2, CREB signaling, cAMP/protein kinase A pathway, MAPK/ERK1/2 pathway, type 1 diabetes, type 2 diabetes, islets
- MeSH terms
- Exenatide, Animals, Cell Line, Cells, Cultured, Dose-Response Relationship, Drug, Glucose, Humans, Male, Peptides, Venoms, Oligonucleotide Array Sequence Analysis, RGS Proteins, Gene Silencing, Gene Expression Profiling, Cell Proliferation, Insulin-Secreting Cells, Mice, Cyclic AMP Response Element Modulator, Glucagon-Like Peptide 1, Dual-Specificity Phosphatases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.